Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.
Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.